

VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev F

Release Notes Version 1.0

Department of Veterans Affairs

Enterprise Project Management Office

This page intentionally left blank.

# Revision History

| **Date** | **Revision** | **Description** | **Author** |
| --- | --- | --- | --- |
| 07/01/20 | 1.0 | VBECS 2.3.2 Rev FInitial version (Task 1195856) | BBM Team |

This page intentionally left blank.

Table of Contents

[Revision History i](#_Toc44507255)

[Introduction 1](#_Toc44507256)

[Changed Features and Functions 1](#_Toc44507257)

[Untestable System-Level Maintenance Changes 1](#_Toc44507258)

[VistA Software Dependencies 1](#_Toc44507259)

[VBECS User Documents 2](#_Toc44507260)

[Customer Support 4](#_Toc44507261)

[Problems? 4](#_Toc44507262)

[References 4](#_Toc44507263)

[VBECS SharePoint Site 4](#_Toc44507264)

[Installation Qualification (IQ) Documentation 4](#_Toc44507265)

[Validation Planning 6](#_Toc44507266)

[Table 1: Updates by Option 7](#_Toc44507267)

[Table 2: New Blood Products for COVID-19 Treatment 11](#_Toc44507268)

[Table 3: Other Blood Products not related to COVID-19 treatment 12](#_Toc44507269)

[Table 4: Possible Modifications for Newly Added Products 13](#_Toc44507270)

This page intentionally left blank.

# Introduction

*VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev F Release Notes* contains information for changes and corrections made to VBECS in the 2.3.2 Rev F patch.

Perform a local evaluation and risk assessment of the changes to determine the requirements for local validation of the changes, including documentation of the assessment activities. See Validation Planning.

# Changed Features and Functions

This revision letter patch release is centrally focused around enhancing and resolving issues with CPRS Blood Bank Report, providing solutions to customer reported issues, and providing additional blood product updates released from International Council for Commonality in Blood Banking Automation, Inc. (ICCBBA) in releases 7.36.2 through 7.37.0. In addition, VBECS System Maintenance fixes (untestable by the user) are included.

Table 1: Updates by Option provides a complete list of included changes.

For a full list of new product codes see Tables 2, 3 and 4.

## Untestable System-Level Maintenance Changes

* Workload Processing 209780
	+ Successfully processed workload records retransmitted by VistA won't cause database errors.
* VBECS Database 1181040
	+ Database changes suggested by Microsoft Data Migration Assistant in preparation for future upgrade to SQL Server 2016.
* VistA Mailman 939717
	+ Mailman will now report on both Version 2.0 along with Version 1.0 patches.

## VistA Software Dependencies

* VBEC\*2\*8, LR\*5.2\*535, and OR\*3\*527

CPRS Blood Bank Report changes described in Table 1 rely on these VistA patches. If you notice that your report does not contain these changes, please contact your local VistA administrator to verify that all three patches were installed.

## VBECS User Documents

The following is a list of all the VBECS user documents that apply to the VBECS 2.3.2 Rev F patch release. The **Updated** column identifies the documents that have been updated with this VBECS 2.3.2 Rev F revision letter patch release.

These user documents are available from the VA Software Document Library (VDL) at <https://www.va.gov/vdl/application.asp?appid=182>.

|  |  |  |
| --- | --- | --- |
| **User Document** | **Version** | **Updated**  |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 User Guide* | 5.0 | Yes |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Administrator User Guide* | 3.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Known Defects and Anomalies* | 4.0 | Yes |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Technical Manual-Security Guide* | 2.0 | Yes |
| *VistA Blood Establishment Computer Software (VBECS) - Echo Interface Configuration and Setup Guide* | 5.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - Erytra Interface Configuration and Setup Guide* | 2.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - ProVue Interface Configuration and Setup Guide* | 5.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - Vision Interface Configuration and Setup Guide* | 4.0 | No |

The following is a list of all the VBECS FAQ documents that apply to the VBECS 2.3.2 Rev F patch release. The **Updated** column identifies the documents that have been updated with this VBECS 2.3.2 Rev F revision letter patch release.

These FAQ documents are available from the VA SharePoint site at REDACTED.

|  |  |  |
| --- | --- | --- |
| **FAQ Document** | **Version** | **Updated**  |
| *FAQ ABO subgroup Interpretations* | 11/22/16 | No |
| *FAQ Ancillary VistA Validation* | 11/28/17 | No |
| *FAQ Antibodies with No Antigen Negative Requirement* | 10/15/14 | No |
| *FAQ Blood Product Table Processes* | 03/28/19 | No |
| *FAQ CAP Comprehensive Transfusions Medicine Crossmatch Survey* | 11/22/16 | No |
| *FAQ Compound Antibodies* | 02/27/13 | No |
| *FAQ CPRS VBECS Order Details* | 04/01/09 | No |
| *FAQ Database Conversion Oddballs* | 09/15/09 | No |
| *FAQ Documenting Unhandled Exceptions* | 05/21/07 | No |
| *FAQ Handling ABO Incompatible Transfusion Situations* | 09/23/14 | No |
| *FAQ How to File a New Service Request for Changes to VBECS* | 12/08/16 | No |
| *FAQ How to take faster screen shots from Remote Desktop Session* | 12/17/14 | No |
| *FAQ Identifying a Comparable Blood Product Code* | 03/28/19 | No |
| *FAQ Local Facilities* | 06/12/20 | Yes |
| *FAQ Modification Target Not Available* | 11/28/17 | No |
| *FAQ Multidivisional QC Rack Workaround* | 11/28/17 | No |
| *FAQ Order Status Clarification* | 11/15/17 | No |
| *FAQ Polyspecific AHG Not Used for Testing* | 01/29/10 | No |
| *FAQ Proper Use of PIV Card with VBECS* | 11/04/19 | No |
| *FAQ QC Setup* | 01/29/10 | No |
| *FAQ Retesting QC* | 11/01/11 | No |
| *FAQ Retrieving an Expired Order* | 12/07/17 | No |
| *FAQ The Difference Between Transfusion Only and Full Service Facility Types* | 02/08/10 | No |
| *FAQ VBECS Blood Product Hierarchy* | 03/28/19 | No |
| *FAQ VBECS Computer Crossmatch Decision Tree* | 02/08/12 | No |
| *FAQ Weak D Policy* | 01/11/10 | No |
| *FAQ Workload Assignments Single vs Batch Processing* | 07/01/20 | Yes |

# Customer Support

## Problems?

Contact your Local Office of Information Technology (OIT) or Laboratory Information Manager (LIM) if you encounter VistA or CPRS connection problems and for training support **before** contacting the Service Desk (SD).

|  |
| --- |
| * Please ensure local contact information is available at all times. SD support will engage Enterprise Operations (EO) personnel as needed.
* Problems with connectivity to VistA and CPRS may require personnel from EO with VBECS server administrator access and VistA IT support access.
* If you experience a Food and Drug Administratin (FDA) reportable adverse event (patient death or serious injury) that VBECS may have caused or contributed to, contact the Service Desk directly to enter a ticket for Blood Bank software support.
 |

If the problem remains unresolved after local VistA triage, call the Service Desk (below) and specify the Enterprise Application be set as VistA Blood Establishment Computer Software. This will cause the Assignment group to default to NTL Alert Blood Bank & VBECS, which alerts the Clin2 team.

**Service Desk Contact**

REDACTED.

## References

* *ISBT128 Standard Technical Specification v 5.10.0*

|  |
| --- |
| * *Blood Product Revisions ICCBBA Version 7.37.0, June 5th 2020*
 |

## VBECS SharePoint Site

The VBECS SharePoint site provides a location for additional information related to the VBECS application such as FAQs, installation status, and release history.

REDACTED.

# Installation Qualification (IQ) Documentation

The expedited patch installation process will continue with the installation of VBECS 2.3.2 Rev F.

|  |
| --- |
|  **Test Account Upgrade to VBECS 2.3.2 Revision F** |
| Required Patch Installation | VistA Patch: VBEC\*2\*8, LR\*5.2\*535, and OR\*3\*527Server Patch: VBECS 2.3.2 Revision F |
| Installation Process for VBECS 2.3.2 Rev F | Installed by the BBM team, all sites will be installed in one day. The date of installation will be communicated through a ListServ announcement. |
| Installation Process for VBEC\*2\*8, LR\*5.2\*535, and OR\*3\*527 | Installed by IT Support Staff according to patch description and local policy. |
| Expected Downtime | None |
| Installation Communication for VBECS 2.3.2 Rev F | The planned completion time for all test installs will be provided on the VBECS SharePoint site. |
| Site Responsibility | * Join VBECS-L message board on ListServ, if needed.
* Please communicate any changes to your site supervisor and Point of Contact (POC) since the last patch install to the BBM team to the email group “VA OIT BBM Team”.
 |
| Site Record of Patch Installation | Sites should take and save a screenshot of the VBECS Help, About window after the Test installation is performed. This displays the VBECS updated version information.  |

|  |
| --- |
|  **Production Account Upgrade to VBECS 2.3.2 Revision F** |
| Required Patch Installation | VistA Patch: VBEC\*2\*8, LR\*5.2\*535, and OR\*3\*527 Server Patch: VBECS 2.3.2 Revision F |
| Installation Process for VBECS 2.3.2 Rev F | Installed by the BBM team, all sites will be installed in one day. The date of installation will be communicated through a ListServ announcement. |
| Installation Process for VBEC\*2\*8, LR\*5.2\*535, and OR\*3\*527 | Installed by IT Support Staff according to patch description and local policy. |
| Expected Downtime | You will be able to use VBECS during the patch installation. VBECS installation on your production account only lasts a few minutes and is invisible to users.If you encounter any disruption or errors while viewing or printing reports during the installation, try again after a few minutes. |
| Installation Communication for VBECS 2.3.2 Rev F | The status of production installs will be provided on the VBECS SharePoint site. |
| Site Responsibility | * Perform local validation, training, and set-up requirements prior to Production installation.
* Join VBECS-L message board on ListServ, if needed.
* Please communicate any changes to your site supervisor and Point of Contact (POC) since the last patch install to the BBM team to the email group “VA OIT BBM Team”.
 |
| Site Record of Patch Installation | Sites should take and save a screenshot of the VBECS Help, About window after Production installation is performed. This displays the VBECS updated version information.  |

# Validation Planning

The following is a flowchart to help assess changes for validation planning.



# Table 1: Updates by Option

| ID | Option | **Problem Summary** | **Change Summary** | **Validation Scenario** | **Change applies to my facility. (Y/N)** | **Local risk Assessment****(Low, Med, High)** | **SOP revision required. If yes, identify it.** | **Staff training needed.****(Y/N)** | **Scenarios or validation must be performed.****(Y/N)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | CPRS Blood Bank Report8227929704311093252214353118656312301751247284906324434646 | Enhancements and defect fixes in CPRS Blood Bank Report. | Added patient’s antigen negative requirements and component requirements right after patient’s antibodies. | Validate that patient’s antigen negative requirements and component requirements are now included in the report. |  |  |  |  |  |
| Added Issue Date, Product Code and Product Name to the Available/Issued Units section. | Validate that Available/Issued Units section contains Issue/Date (only for issued units, otherwise blank), Product Code and Product Name for each unit listed in that section. |  |  |  |  |  |
| Removed reaction strengths for DAT tests from the Diagnostic tests section. Added Specimen Collection Date and Specimen UID to this section. | Validate that for DAT tests the reaction strengths are no longer displayed. Only DAT interpretations are included. Also verify that Specimen Collection Date and Specimen UID are included in this section. |  |  |  |  |  |
| The report now distinguishes between two TAS tests performed at the same date and time. The report will now display results for both TAS instead of just one. | Perform validation only if you were directly affected by this defect.Run two TAS tests on two samples drawn from one patient in the automated instrument so that they complete at the same date and time. Accept results in VBECS and verify that both TAS results are showing on CPRS Blood Bank Report. |  |  |  |  |  |
| Added reference range for ABS and DAT tests to the Diagnostic Tests section. | Validate that there is a new comment at the bottom of the Diagnostic tests section that describes reference ranges for ABS and DAT tests. (hint: you must have at least one ABS or DAT test result present for a given patient for the reference range comment to show). |  |  |  |  |  |
| Removed cancelled orders from Component Requests section of the report. | Validate that cancelled orders no longer show in the Component Requests section. Place any component order in CPRS. Verify that it shows in CPRS Blood Bank Report. Cancel an order in VBECS. Verify that the order no longer shows on the report. |  |  |  |  |  |
| Enhanced Transfused Units section of the CPRS Blood Bank Report. It now contains detailed information about each transfusion including Unit ID, Product Code, Product Name and Unit ABO/Rh. | Validate that the Transfused Units section of the report lists all patient’s transfusions including Unit ID, Product Code, Product Name and Unit ABO/Rh. |  |  |  |  |  |
| Optimized the display of canned comments to have one comment display for entire antibody section instead of one comment per antibody. | No validation required. |  |  |  |  |  |
| 2 | Blood Products1267523 | Update blood product table with new ICCBBA blood product codes from version 7.36.2 through 7.37.0. | New blood products were added to VBECS.For a full list of new product codes for COVID-19 treatment, see Table 2.For all other blood products added by ICCBBA that are not related to COVID-19 treatment see Table 3.For possible modifications for new blood products see Table 4. | Validate only blood products that you may receive from your supplier. Use Tools, Blood Products to associate the blood products with an active facility. |  |  |  |  |  |
| 3 | Cost Accounting Report1245810 | The value of Special Testing Cost displayed in the Incoming Shipment section of the report does not account for any cost correction made via Edit Financial Data option. | The value of Special Testing will now reflect any correction made. | Validate only if you were affected by this defect.Enter new blood unit into VBECS. Set its Special Testing Cost to a non-zero value. Go to Blood Units -> Edit Financial Data and modify special testing cost for this blood unit. Run Cost Accounting Report and verify that the modified Special Testing Cost shows in the Incoming Shipment section. |  |  |  |  |  |
| 4 | Unit History Report1212351 | Name of Collection Facility in the Outgoing Shipment section does not show correctly if the facility name was changed after the shipment occurred. | The collection facility will show its original name if it was changed after the shipment occurred. | No validation required. |  |  |  |  |  |
| 5 | Invalidate Patient Test Results210120 | VBECS would crash when trying to invalidate crossmatch on a blood unit that was quarantined during issue (units marked as unsatisfactory during issue). | VBECS will no longer crash. | No validation required. |  |  |  |  |  |
| 6 | Record Locking975331 | A defect caused some record locks to not clear properly preventing users from accessing patient records. | Record locks will now clear properly. | No validation required. |  |  |  |  |  |
| 7 | CPRS Order Alert1200546 | Recently introduced VBECS CPRS Order Alert icon was causing locking issues in the database. | CPRS Order Alert icon will no longer negatively affect the performance of the VBECS database. | No validation required. |  |  |  |  |  |
| 8 | Outgoing Shipment208815 | Outgoing shipment type of “Send to other VA hospital” is unused. | Shipment type of “Send to other VA hospital” was removed from VBECS database. | No validation required. |  |  |  |  |  |
| 9 | MSBOS1190786 | Spelling errors in the surgical procedure names for Maximum Surgical Blood Order Schedule (MSBOS). | Changed Esophogeal Resection to Esophageal Resection.Changed Esophogectomy to Esophagectomy.Changed Cholostomy to Colostomy.Changed Femoral-Popiteal Bypass to Femoral-Popliteal Bypass | No validation required. |  |  |  |  |  |

# Table 2: New Blood Products for COVID-19 Treatment

| **Component** | **Product Code** | **Modifiable** | **Product Type** | **Long Name** | **Short Name** | **Maximum Storage Hours** |
| --- | --- | --- | --- | --- | --- | --- |
| FRESH FROZEN PLASMA | E9866 | No | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Not for tx or mnf|COVID-19 | PLASMA AFR Conv ACD-A NMT COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9867 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9868 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN 1C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9869 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN 2C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9870 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN 3C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9871 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN 4C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9872 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN IRD COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9873 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN IRD 1C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9874 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN IRD 2C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9875 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 | PLASMA Conv AFR Thaw ACD-A OPN IRD 3C COVID-19 | 24 |
| FRESH FROZEN PLASMA | E9877 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CPD/XX/<=-25C|Riboflavin-treated|COVID-19 | PLASMA Conv CPD Ribo COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9878 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-25C|COVID-19 | PLASMA AFR Conv ACD-A COVID-19 | 8760 |

# Table 3: Other Blood Products not related to COVID-19 treatment

| **Component** | **Product Code** | **Modifiable** | **Product Type** | **Long Name** | **Short Name** | **Maximum Storage Hours** |
| --- | --- | --- | --- | --- | --- | --- |
| PLATELETS | E9876 | Yes | Thawed POOLED PLATELETS | Thawed POOLED PLATELETS|DMSO/XX/20-24C|ResLeu:<1E6|Buffy coat plts prep|Psoralen-treated | PLT Pool Thaw DMSO LUKOPR BUFCT Psoraln | 4 |
| RED BLOOD CELLS | E9879 | Yes | Apheresis RED BLOOD CELLS | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | RBC AFR CP2D>AS3 IRD LUKOPR PA | 672 |
| RED BLOOD CELLS | E9880 | Yes | Apheresis RED BLOOD CELLS | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | RBC AFR CP2D>AS3 IRD LUKOPR PA 1C | 672 |
| RED BLOOD CELLS | E9881 | Yes | Apheresis RED BLOOD CELLS | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | RBC AFR CP2D>AS3 IRD LUKOPR PA 2C | 672 |
| PLATELETS | E9882 | Yes | POOLED PLATELETS | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | PLT Pool CPD OPN LUKOPR PLS Red/SAL Add BUFCT 4U | 4 |
| PLATELETS | E9883 | Yes | POOLED PLATELETS | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | PLT Pool CPD OPN IRD LUKOPR PLS Red/SAL Add BUFCT 4U | 4 |
| FRESH FROZEN PLASMA | E9884 | Yes | Liquid PLASMA | Liquid PLASMA|CPDA-1/XX/refg|ResLeu:<5E6 | PLASMA Liq CPDA-1 LUKOPR | 960 |
| FRESH FROZEN PLASMA | E9885 | Yes | Thawed POOLED PLASMA | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors | PLASMA Pool Thaw CP2D OPN 2DNR | 4 |
| FRESH FROZEN PLASMA | E9886 | Yes | Thawed POOLED PLASMA | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors | PLASMA Pool Thaw CPD OPN 2DNR | 4 |

# Table 4: Possible Modifications for Newly Added Products

| **Modification** | **Method** | **Source Product Code** | **Source Product Name** | **Target Product Code** | **Target Product Name** |
| --- | --- | --- | --- | --- | --- |
| Thaw | CLOSED | E9877 | CONVALESCENT PLASMA|CPD/XX/<=-25C|Riboflavin-treated|COVID-19 | E9861 | Thawed CONVALESCENT PLASMA|CPD/XX/refg|Riboflavin-treated|COVID-19 |
| Thaw | CLOSED | E9878 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-25C|COVID-19 | E9752 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 |
| Freeze | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E5102 | Frozen Apheresis RED BLOOD CELLS|None/XX/<=-65C|Open|Irradiated|ResLeu:<5E6 |
| Freeze | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E5103 | Frozen Apheresis RED BLOOD CELLS|None/XX/<=-65C|Open|Irradiated|ResLeu:<5E6|1st container |
| Freeze | OPEN | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E5104 | Frozen Apheresis RED BLOOD CELLS|None/XX/<=-65C|Open|Irradiated|ResLeu:<5E6|2nd container |
| Irradiate | CLOSED | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 |
| Irradiate | CLOSED | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 |
| Irradiate | CLOSED | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 |
| Irradiate | CLOSED | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5229 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6 |
| Irradiate | CLOSED | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E8076 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Buffy coat plts prep|4 units |
| Irradiate | CLOSED | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units |
| Leukoreduce | CLOSED | E2463 | Liquid PLASMA|CPDA-1/XX/refg | E9884 | Liquid PLASMA|CPDA-1/XX/refg|ResLeu:<5E6 |
| Rejuvenate | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E5657 | Rejuvenated Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added |
| Rejuvenate | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E5993 | Rejuvenated Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6 |
| Rejuvenate | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E5050 | Rejuvenated Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|1st container |
| Rejuvenate | OPEN | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E5051 | Rejuvenated Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|2nd container |
| Split/Divide | CLOSED | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 |
| Split/Divide | CLOSED | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 |
| Split/Divide | CLOSED | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 |
| Split/Divide | CLOSED | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 |
| Split/Divide | CLOSED | E9871 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 | E9871 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 |
| Split/Divide | CLOSED | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 |
| Split/Divide | CLOSED | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 |
| Split/Divide | CLOSED | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 |
| Split/Divide | CLOSED | E9876 | Thawed POOLED PLATELETS|DMSO/XX/20-24C|ResLeu:<1E6|Buffy coat plts prep|Psoralen-treated | E9876 | Thawed POOLED PLATELETS|DMSO/XX/20-24C|ResLeu:<1E6|Buffy coat plts prep|Psoralen-treated |
| Split/Divide | CLOSED | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added |
| Split/Divide | CLOSED | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container |
| Split/Divide | CLOSED | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container |
| Split/Divide | CLOSED | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units |
| Split/Divide | CLOSED | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units |
| Split/Divide | CLOSED | E9884 | Liquid PLASMA|CPDA-1/XX/refg|ResLeu:<5E6 | E9884 | Liquid PLASMA|CPDA-1/XX/refg|ResLeu:<5E6 |
| Split/Divide | CLOSED | E9885 | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors | E9885 | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors |
| Split/Divide | CLOSED | E9886 | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors | E9886 | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors |
| Split/Divide | OPEN | E8835 | Thawed POOLED PLASMA|CPD/XX/refg|From 2 donors | E9886 | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors |
| Split/Divide | OPEN | E8838 | Thawed POOLED PLASMA|CP2D/XX/refg|From 2 donors | E9885 | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors |
| Split/Divide | OPEN | E9752 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 |
| Split/Divide | OPEN | E9762 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|COVID-19 | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 |
| Split/Divide | OPEN | E9763 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|COVID-19 | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 |
| Split/Divide | OPEN | E9764 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|COVID-19 | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 |
| Split/Divide | OPEN | E9765 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|COVID-19 | E9871 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 |
| Split/Divide | OPEN | E9793 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 |
| Split/Divide | OPEN | E9819 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|1st container|COVID-19 | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 |
| Split/Divide | OPEN | E9820 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|2nd container|COVID-19 | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 |
| Split/Divide | OPEN | E9821 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|3rd container|COVID-19 | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 |
| Split/Divide | OPEN | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 | E9867 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|COVID-19 |
| Split/Divide | OPEN | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 | E9868 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|1st container|COVID-19 |
| Split/Divide | OPEN | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 | E9869 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|2nd container|COVID-19 |
| Split/Divide | OPEN | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 | E9870 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|3rd container|COVID-19 |
| Split/Divide | OPEN | E9871 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 | E9871 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|4th container|COVID-19 |
| Split/Divide | OPEN | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 | E9872 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|COVID-19 |
| Split/Divide | OPEN | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 | E9873 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|1st container|COVID-19 |
| Split/Divide | OPEN | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 | E9874 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|2nd container|COVID-19 |
| Split/Divide | OPEN | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 | E9875 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Open|Irradiated|3rd container|COVID-19 |
| Split/Divide | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E6796 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added |
| Split/Divide | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E6797 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added|1st container |
| Split/Divide | OPEN | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E6798 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added|2nd container |
| Split/Divide | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units |
| Split/Divide | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units |
| Split/Divide | OPEN | E9885 | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors | E9885 | Thawed POOLED PLASMA|CP2D/XX/refg|Open|From 2 donors |
| Split/Divide | OPEN | E9886 | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors | E9886 | Thawed POOLED PLASMA|CPD/XX/refg|Open|From 2 donors |
| Wash | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E4145 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6 |
| Wash | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E5666 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added |
| Wash | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E4560 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|1st container |
| Wash | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E5664 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added|1st container |
| Wash | OPEN | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E4561 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|2nd container |
| Wash | OPEN | E9881 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|2nd container | E5665 | Washed Apheresis RED BLOOD CELLS|None/XX/refg|Open|Irradiated|ResLeu:<5E6|Plasma added|2nd container |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E2921 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6 |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5927 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|2 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5928 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|3 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5929 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|4 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5930 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|5 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5931 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|6 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5932 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|7 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5933 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|8 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E6367 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|Buffy coat plts prep|4 units |
| Wash | OPEN | E9882 | POOLED PLATELETS|CPD/XX/20-24C|Open|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E7634 | Washed POOLED PLATELETS|None/XX/20-24C|Open|ResLeu:<5E6|Buffy coat plts prep|5 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E2920 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6 |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5888 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Supernat reduced |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5920 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|2 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5921 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|3 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5922 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|4 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5923 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|5 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5924 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|6 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5925 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|7 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E5926 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|8 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E6368 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Buffy coat plts prep|4 units |
| Wash | OPEN | E9883 | POOLED PLATELETS|CPD/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Plasma reduced/Saline added|Buffy coat plts prep|4 units | E7635 | Washed POOLED PLATELETS|None/XX/20-24C|Open|Irradiated|ResLeu:<5E6|Buffy coat plts prep|5 units |
| Freeze | OPEN | E9879 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added | E5102 | Frozen Apheresis RED BLOOD CELLS|None/XX/<=-65C|Open|Irradiated|ResLeu:<5E6 |
| Freeze | OPEN | E9880 | Apheresis RED BLOOD CELLS|CP2D>AS3/XX/refg|Irradiated|ResLeu:<5E6|Plasma added|1st container | E5103 | Frozen Apheresis RED BLOOD CELLS|None/XX/<=-65C|Open|Irradiated|ResLeu:<5E6|1st container |

This is the last page of *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev F Release Notes*.